GO FOR the GOLD DEVICE1
Fixed dose triple therapy in a pMDI for patients with moderate to very severe COPD
SCAN TO ORDER BREZTRI ® SAMPLE
INDICATION: BREZTRI AEROSPHERE ® is indicated as a maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe COPD who require treatment with a combination of ICS, LABA, and LAMA. 1
BREZTRI AEROSPHERE ® is not indicated for the initiation of therapy in COPD. 1
SAFETY: In ETHOS, adverse events that occurred in ≥3 % of patients overall for BREZTRI ® and GLY / FORM were nasopharyngitis, COPD, upper respiratory tract infection, pneumonia and bronchitis. 2 The incidence of confirmed pneumonia was 4.2 % with BREZTRI ® and 2.3 % with GLY / FORM. 1, 2 Please review Product Information for information on other Precautions and Adverse Effects.
PBS Information: Authority required( STREAMLINED) for the treatment of COPD. Refer to PBS for full authority information.
PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING. PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR WWW. ASTRAZENECA. COM. AU / PI OR BY SCANNING THIS QR CODE.
SCAN QR CODE to see full BREZTRI ® Product Information
COPD = chronic obstructive pulmonary disease; FORM = formoterol; GLY = glycopyrronium; ICS = inhaled corticosteroid; LABA = long-acting beta 2 agonist; LAMA = long-acting muscarinic antagonist; pMDI = pressurised Metered Dose Inhaler. References: 1. BREZTRI AEROSPHERE ® Approved Product Information. 2. Rabe F et al. N Engl J Med. 2020; 383( 1): 35 – 48.
BREZTRI ® and AEROSPHERE ® are registered trademarks of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www. astrazeneca. com. au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https:// contactazmedical. astrazeneca. com. 002512. 2743. AU-21579. January 2025.